ProMIS Neurosciences Inc. (PMN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in ProMIS Neurosciences Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

ProMIS Neurosciences Inc. (PMN) has returned 86.08% so far this year and -26.96% over the past 12 months. Looking at the last ten years, PMN has achieved an annualized return of 28.01%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Jul 17, 2007, PMN's average daily return is +1.59%, while the average monthly return is +28.02%. At this rate, your investment would double in approximately 0.2 years.

Historically, 38% of months were positive and 62% were negative. The best month was Jul 2022 with a return of +5,851.0%, while the worst month was Mar 2015 at -73.2%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.

On a daily basis, PMN closed higher 24% of trading days. The best single day was Jul 1, 2022 with a return of +6,762.8%, while the worst single day was Nov 6, 2008 at -69.2%.

ProMIS Neurosciences Inc. has an annualized alpha of 4661.08%, beta of 1.29, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 18, 2007.

• This stock participated in 174.40% of S&P 500 Index downside but only 150.22% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PMN ranks 42 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for ProMIS Neurosciences Inc. (PMN) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ProMIS Neurosciences Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ProMIS Neurosciences Inc. was 98.80%, occurring on Mar 26, 2015. Recovery took 1823 trading sessions.

The current ProMIS Neurosciences Inc. drawdown is 94.51%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ProMIS Neurosciences Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ProMIS Neurosciences Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.